Compare TransMedics Group Inc (TMDX) vs Unilever plc (UL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Unilever plc — how do they compare? TransMedics Group Inc trades at $79.01 (market cap $2.74B), while Unilever plc trades at $61.66 (market cap $131.63B). The key difference: Unilever plc is far larger — about 48× TransMedics Group Inc's market cap, and Unilever plc pays a 3.43% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TransMedics Group Inc for 24 Days and Unilever plc for 112 Days on average.
| TMDX | UL | |
|---|---|---|
Market Cap | $2.74B | $131.63B |
Volume | 949,331 | 2,978,741 |
Sector | Health | Consumer Staples |
52-Week High | $150.42 | $74.59 |
52-Week Low | $61.99 | $55.05 |
Typical Hold Time | 24 Days | 112 Days |
Enterprise Value | $3.13B | $156.65B |
Dividend Yield | — | 3.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TMDX trades at $81.07, up 0.98% today, but faces a bearish technical signal with recent price weakness. Fundamentally, the company reported strong 2025 results with $605.49M revenue and $190.29M net income, though 2026 projections show margin compression. Recent news highlights insider buying and ongoing legal investigations into fiduciary duties, creating mixed sentiment.
The stock offers potential upside to the $99.75 consensus target, supported by a 69% buy rating from analysts, but risks include earnings misses, margin pressure from heavy investment, and legal overhangs. Execution on growth amid rising costs remains critical for sustaining its premium valuation.
Unilever (UL) trades at $60.98, up 0.3% on the day, amid a bearish technical signal and mixed earnings performance. The company reported Q2 2026 EPS of $1.83, narrowly missing the $1.84 estimate, continuing a trend of recent misses. Financially, UL maintains strong profitability with an 18.32% net income margin and 54.56% ROE, though revenue declined to $50.5B in 2025. Analyst sentiment is divided with a Hold consensus, while news highlights strategic shifts including the planned food business merger with McCormick.
The outlook balances high profitability and emerging market exposure against execution risks from portfolio restructuring and recent earnings misses. The stock's valuation at a P/E of 21.32 appears reasonable relative to historical margins, but investor caution is warranted given the bearish technical trend and regulatory scrutiny of the McCormick deal. Upside potential hinges on successful integration and volume growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Unilever plc
Unilever is a diversified personal product (42% of 2021 sales by value), home care (20%), and packaged food (38%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Lipton teas, Axe and Dove skin products, and the TRESemme haircare brand. The firm has been acquisitive in recent years
Read more on UL →
